Professional development Vacancies

The benefit of medicinal products containing ifosfamide as solutions for infusion continues to outweigh the risks

18.03.2021 2252 views

The PRAC concluded that the benefit of ifosfamide infusion solutions continues to outweigh the risks in the treatment of various types of malignant neoplasms, including various solid tumors and blood cancers such as lymphomas.

The PRAC review was initiated because two recent studies1,2 showed that the risk of encephalopathy associated with the use of ifosfamide infusion solutions is higher than with the powder form. Ifosfamide-induced encephalopathy is a common and known risk and, as a rule, is reversible.

The PRAC committee reviewed all available data and concluded that the increased risk of encephalopathy associated with the use of ifosfamide infusion solutions can be neither confirmed nor excluded because of data limitations. The PRAC committee recommended updating the existing warning on ifosfamide-induced encephalopathy in the instructions for medical use with the latest information on this adverse reaction, including its characteristics and risk factors, as well as emphasizing the need for careful patient monitoring.

Companies marketing ifosfamide as a solution for infusion must conduct studies on the stability of these medicinal products in order to establish optimal storage conditions.

Information for patients

  • encephalopathy is a very common, known adverse effect of treatment with ifosfamide and is, as a rule, reversible. Two recent studies showed that the use of ifosfamide solutions may increase the risk of this adverse effect compared with the powder form. However, an in-depth review of all available data could neither confirm nor exclude this increased risk;
  • tell your doctor immediately if you experience confusion, drowsiness, fainting, hallucinations, delusions (false beliefs), blurred vision, perceptual disorder (difficulty understanding information received through the senses), movement problems such as muscle spasms or contractions, restlessness, slow or irregular movements, loss of bladder control, and convulsions (seizures);
  • discuss with your doctor before you are prescribed medicinal products containing ifosfamide if you have previously been treated with another cancer drug called cisplatin;
  • inform your doctor if you have used medicinal products that affect the brain, such as medicines for the treatment or prevention of vomiting and nausea, sleeping pills, opioid pain relievers, or allergy medicines;
  • if you have any concerns about your treatment, you should discuss them with your doctor.

Information for healthcare professionals

  • administration of ifosfamide can cause encephalopathy and other neurotoxic effects; these known, very common adverse effects are generally reversible;
  • a review of all available data on encephalopathy caused by ifosfamide concluded that an increased risk of encephalopathy with the use of ifosfamide as a solution can be neither confirmed nor excluded due to limitations of the data;
  • the existing warnings in the section “Special warnings and precautions for use” of the instructions for medical use will be revised taking into account the following information:
    • ifosfamide-induced CNS toxicity can manifest from several hours to several days after administration and in most cases resolves within 48-72 hours after discontinuation of ifosfamide. If CNS toxicity develops, ifosfamide use should be discontinued;
    • patients should be closely monitored for symptoms of encephalopathy, particularly if they are at increased risk of developing encephalopathy. Symptoms may include confusion, drowsiness, coma, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, and seizures;
    • CNS toxicity is probably dose-dependent. Risk factors for the development of ifosfamide-associated encephalopathy are hypoalbuminemia, impaired renal function, low performance status, pelvic disease, and previous or concomitant nephrotoxic treatments, including cisplatin;
    • due to the potential for additive effects, medicinal products acting on the CNS (such as antiemetics, sedatives, narcotics, or antihistamines) should be used with particular caution or, if necessary, discontinued in the case of encephalopathy caused by ifosfamide.

More about the medicinal product

Medicinal products containing ifosfamide are used to treat several types of cancer, including various solid tumors and lymphomas. It is administered intravenously and is authorized as a ready-to-use solution, concentrate for solution, and powder for solution for infusion in Germany and France. In most other EU Member States it is available only as a powder for solution for infusion.

More about the procedure

The review of medicinal products containing ifosfamide was initiated at the request of the French regulatory agency pursuant to Article 31 of Directive 2001/83/EC.

The review was conducted by the PRAC, which made a number of recommendations. The PRAC recommendations will now be sent to the Coordination Group for Mutual Recognition and Decentralized Procedures (CMDh), which will reach a conclusion.

Link

https://www.ema.europa.eu/en/medicines/human/referrals/ifosfamide-solutions

https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_en.pdf

Перелік лікарських засобів, що містять ifosfamide у вигляді розчинів для інфузій, що дозволені для медичного застосування на території України (за даними Державного реєстру України станом на 12.03.2021)